Recent observations indicate that Sertoli cell aromatase activity decreases when cultures are performed at high density. Increasing cell density modifies cell shape in culture from flat cells with visible anchorage sites and abundant intercellular spaces to cells with higher profiles that form a uniform epithelial sheet with no intercellular spaces. Changes in cell architecture are associated with reorganization of the cytoskeleton components. In this report, we have tested whether disruption of microfilaments and microtubules by cytochalasin B and colchicine, respectively, has any effect on the ability of FSH to stimulate aromatase activity. Cytochalasin B, but not colchicine, significantly enhanced aromatase activity in FSH and dbcAMP stimulated cells. The increase in aromatase activity was accompanied by a striking change in cell morphology. Time course studies suggested that microfilament organization is involved in some metabolic event which occurs sometime between 2 and 4 h after the initial steps of FSH action. The reversibility of the biochemical and morphological changes induced by cytochalasin B was demonstrated. The effect of cytochalasin B was observed in high but not in low-density cultures, suggesting that microfilament organization in high-density cultures constrains FSH stimulation of aromatase activity. The last two observations made suggest the existence of a dynamic interplay between microfilament organization and FSH action in Sertoli cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0303-7207(95)03587-w | DOI Listing |
Cureus
December 2024
Internal Medicine and Family Medicine, Larkin Community Hospital Palm Springs Campus, Miami, USA.
The purpose of this review is to explore the relationship between weight loss (WL), specifically reductions in body mass index (BMI), and increases in testosterone levels. Obesity and excess body fat are linked to reduced testosterone levels, which can lead to metabolic dysfunctions, reduced libido, and diminished muscle mass. To attain this purpose, this review will summarize current evidence on how weight reduction interventions, including dietary changes, exercise, and bariatric surgery, affect testosterone production in overweight and obese individuals.
View Article and Find Full Text PDFMillions of women worldwide have breast cancer, a common and possibly fatal illness according to WHO Reports. A genetic mutation usually causes breast adenocarcinomas. Only 5-10% of cancers are induced by genetic mutations that develop with age, and the "wear and tear" of general life causes 85-90% of breast cancers.
View Article and Find Full Text PDFBreast
January 2025
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Tamoxifen is an estrogen-receptor (ER) antagonist, used as adjuvant treatment of ER-positive breast cancer. It is converted by CYP2D6 into endoxifen, its most active metabolite. Patients with endoxifen plasma concentrations <16Â nM face a higher risk of recurrence.
View Article and Find Full Text PDFReprod Toxicol
January 2025
Department of Andrology, The First Affiliated Hospital, Hengyang Medical School, University of South China, China. Electronic address:
Molecules
December 2024
Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche "STEBICEF", University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy.
Breast cancer remains one of the most prevalent and lethal malignancies in women, particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately 70% of cases. Traditional endocrine therapies, including aromatase inhibitors, selective estrogen receptor degraders/antagonists (SERDs), and selective estrogen receptor modulators (SERMs), have improved outcomes for metastatic ER+ breast cancer. However, resistance to these agents presents a significant challenge.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!